1. DRUG_A can cause a DIRECTION in the absorption of DRUG_B resulting in a DIRECTION serum concentration and potentially a DIRECTION in efficacy.
2. DRUG_A can cause an DIRECTION in the absorption of DRUG_B resulting in an DIRECTION serum concentration and potentially a worsening of adverse effects.
3. DRUG_A may DIRECTION effectiveness of DRUG_B as a diagnostic agent.
4. DRUG_A may DIRECTION the QTc-prolonging activities of CiprDRUG_A.
5. DRUG_A may DIRECTION the QTc-prolonging activities of DRUG_B.
6. DRUG_A may DIRECTION the QTc-prolonging activities of LevDRUG_A.
7. DRUG_A may DIRECTION the adverse neuromuscular activities of DRUG_B.
8. DRUG_A may DIRECTION the analgesic activities of DRUG_B.
9. DRUG_A may DIRECTION the anticholinergic activities of DRUG_B.
10. DRUG_A may DIRECTION the anticoagulant activities of DRUG_B.
11. DRUG_A may DIRECTION the antihypertensive activities of DRUG_B.
12. DRUG_A may DIRECTION the antiplatelet activities of DRUG_B.
13. DRUG_A may DIRECTION the antipsychotic activities of DRUG_B.
14. DRUG_A may DIRECTION the arrhythmogenic activities of DRUG_B.
15. DRUG_A may DIRECTION the atrioventricular blocking (AV block) activities of DRUG_B.
16. DRUG_A may DIRECTION the bradycardic activities of DRUG_B.
17. DRUG_A may DIRECTION the bronchoconstrictory activities of DRUG_B.
18. DRUG_A may DIRECTION the bronchodilatory activities of DRUG_B.
19. DRUG_A may DIRECTION the cardiotoxic activities of DRUG_B.
20. DRUG_A may DIRECTION the central nervous system depressant (CNS depressant) activities of DRUG_B.
21. DRUG_A may DIRECTION the central nervous system depressant (CNS depressant) and hypertensive activities of DRUG_B.
22. DRUG_A may DIRECTION the central neurotoxic activities of DRUG_B.
23. DRUG_A may DIRECTION the constipating activities of DRUG_B.
24. DRUG_A may DIRECTION the dermatologic adverse activities of DRUG_B.
25. DRUG_A may DIRECTION the diuretic activities of DRUG_B.
26. DRUG_A may DIRECTION the excretion rate of DRUG_B which could result in a DIRECTION serum level and potentially a reduction in efficacy.
27. DRUG_A may DIRECTION the excretion rate of DRUG_B which could result in a higher serum level.
28. DRUG_A may DIRECTION the excretion rate of UrsodeoxyDRUG_A which could result in a higher serum level.
29. DRUG_A may DIRECTION the fluid retaining activities of DRUG_B.
30. DRUG_A may DIRECTION the hepatotoxic activities of DRUG_B.
31. DRUG_A may DIRECTION the hypercalcemic activities of DRUG_B.
32. DRUG_A may DIRECTION the hyperglycemic activities of DRUG_B.
33. DRUG_A may DIRECTION the hyperkalemic activities of DRUG_B.
34. DRUG_A may DIRECTION the hypertensive activities of DRUG_B.
35. DRUG_A may DIRECTION the hypocalcemic activities of DRUG_B.
36. DRUG_A may DIRECTION the hypoglycemic activities of DRUG_B.
37. DRUG_A may DIRECTION the hypokalemic activities of DRUG_B.
38. DRUG_A may DIRECTION the hyponatremic activities of DRUG_B.
39. DRUG_A may DIRECTION the hypotensive activities of DRUG_Aat.
40. DRUG_A may DIRECTION the hypotensive activities of DRUG_B.
41. DRUG_A may DIRECTION the hypotensive and central nervous system depressant (CNS depressant) activities of DRUG_B.
42. DRUG_A may DIRECTION the immunosuppressive activities of DRUG_B.
43. DRUG_A may DIRECTION the myelosuppressive activities of DRUG_B.
44. DRUG_A may DIRECTION the myopathic rhabdomyolysis activities of DRUG_B.
45. DRUG_A may DIRECTION the nephrotoxic activities of DRUG_B.
46. DRUG_A may DIRECTION the neuroexcitatory activities of DRUG_B.
47. DRUG_A may DIRECTION the neuromuscular blocking activities of DRUG_B.
48. DRUG_A may DIRECTION the neurotoxic activities of DRUG_B.
49. DRUG_A may DIRECTION the orthostatic hypotensive activities of DRUG_B.
50. DRUG_A may DIRECTION the ototoxic activities of DRUG_B.
51. DRUG_A may DIRECTION the respiratory depressant activities of DRUG_B.
52. DRUG_A may DIRECTION the sedative activities of DRUG_B.
53. DRUG_A may DIRECTION the serotonergic activities of DRUG_B.
54. DRUG_A may DIRECTION the stimulatory activities of DRUG_B.
55. DRUG_A may DIRECTION the tachycardic activities of DRUG_B.
56. DRUG_A may DIRECTION the thrombogenic activities of DRUG_B.
57. DRUG_A may DIRECTION the ulcerogenic activities of DRUG_B.
58. DRUG_A may DIRECTION the vasoconstricting activities of DRUG_B.
59. DRUG_A may DIRECTION the vasodilatory activities of DRUG_B.
60. DRUG_A may DIRECTION the vasopressor activities of DRUG_B.
61. The absorption of DRUG_B can be DIRECTION when combined with DRUG_A.
62. The bioavailability of DRUG_B can be DIRECTION when combined with DRUG_A.
63. The metabolism of DRUG_B can be DIRECTION when combined with DRUG_A.
64. The metabolism of FosDRUG_A can be DIRECTION when combined with DRUG_A.
65. The metabolism of MethylDRUG_A can be DIRECTION when combined with DRUG_A.
66. The protein binding of DRUG_B can be DIRECTION when combined with DRUG_A.
67. The risk of a hypersensitivity reaction to DRUG_B is DIRECTION when it is combined with DRUG_A.
68. The risk or severity of QTc prolongation can be DIRECTION when DRUG_A is combined with DRUG_B.
69. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with AceDRUG_A.
70. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with ApraDRUG_A.
71. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with ButylDRUG_A.
72. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with ChloroDRUG_A.
73. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with DRUG_A bromide.
74. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with DRUG_A enacarbil.
75. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with DRUG_B.
76. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with DesDRUG_A.
77. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with DiaDRUG_A.
78. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with DihydroDRUG_A.
79. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with EsDRUG_A.
80. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with EthylDRUG_A.
81. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with FluDRUG_A.
82. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with FosDRUG_A.
83. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with HydroDRUG_A.
84. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with HydroxyDRUG_A.
85. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with LevoDRUG_A.
86. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with MeDRUG_A.
87. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with MethDRUG_A bromide.
88. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with MethDRUG_A.
89. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with MethylDRUG_A.
90. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with NorDRUG_A.
91. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with OxybuDRUG_A.
92. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with PseudoDRUG_A.
93. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with TrDRUG_A.
94. The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with TrifluDRUG_A.
95. The risk or severity of bleeding can be DIRECTION when DRUG_A is combined with DRUG_B.
96. The risk or severity of heart failure can be DIRECTION when DRUG_B is combined with DRUG_A.
97. The risk or severity of hyperkalemia can be DIRECTION when DRUG_A is combined with DRUG_B.
98. The risk or severity of hypertension can be DIRECTION when DRUG_B is combined with DRUG_A.
99. The risk or severity of hypotension can be DIRECTION when DRUG_A is combined with DRUG_B.
100. The serum concentration of DRUG_B can be DIRECTION when it is combined with DRUG_A.
101. The serum concentration of FosDRUG_A can be DIRECTION when it is combined with DRUG_A.
102. The serum concentration of the active metabolites of DRUG_B can be DIRECTION when DRUG_B is used in combination with DRUG_A resulting in a loss in efficacy.
103. The serum concentration of the active metabolites of DRUG_B can be DIRECTION when DRUG_B is used in combination with DRUG_A.
104. The therapeutic efficacy of DRUG_B can be DIRECTION when used in combination with DRUG_A.
